NBI-98854 + Placebo

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Oct 1, 2014 → Jul 1, 2016

NCT ID

NCT02274558

About NBI-98854 + Placebo

NBI-98854 + Placebo is a phase 3 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02274558. Target conditions include Tardive Dyskinesia.

What happened to similar drugs?

3 of 6 similar drugs in Tardive Dyskinesia were approved

Approved (3) Terminated (1) Active (3)

🔄levetiracetam + placeboUCBPhase 3

✅Valbenazine Oral CapsuleNeurocrine BiosciencesApproved

🔄NBI-98854Neurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

🔄ValbenazineNeurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02679079	Phase 2	Completed	Mar 23, 2016	Apr 14, 2017	Tourette Syndrome
NCT02581865	Phase 2	Completed	Nov 1, 2015	Dec 1, 2016	Tourette Syndrome
NCT02274558	Phase 3	Completed	Oct 1, 2014	Jul 1, 2016	Tardive Dyskinesia

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors

Product	Company	Stage	Hype Score
Sarizotan	Merck	Pre-clinical	18
levetiracetam + placebo	UCB	Phase 3	40
Valbenazine	Neurocrine Biosciences	Phase 1	18
Valbenazine Oral Capsule	Neurocrine Biosciences	Approved	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 3	37
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-98854	Neurocrine Biosciences	Phase 2	32
Valbenazine	Neurocrine Biosciences	Phase 3	37
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-1065890 + Placebo	Neurocrine Biosciences	Phase 2	39